Oppenheimer initiates NPS Pharmaceuticals (NPSP) at Outperform with a price target of $18....


Oppenheimer initiates NPS Pharmaceuticals (NPSP) at Outperform with a price target of $18. "There are no direct competitors for Gattex and Natpara," writes analyst Boris Peaker, adding that investors shouldn't be wary of "owning a launch name" in this case because the company's "first-in-class compounds [should] generate substantial commercial traction given their therapeutic benefits." Shares +1.81% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs